Civica Inc. is proud to announce that it will be producing insulins for the State of California’s CalRx Biosimilar Insulin Initiative. Once approved, Civica’s biosimilar versions of the most commonly used short-and long-acting insulins will be available to Californians and beyond at prices far lower than what is currently available.
This is great news for diabetic Californians who had previously been forced to choose between life-sustaining medications and living expenses. With Civica’s insulins, they will now have access to more affordable treatments.
Diabetes is an expensive, life-threatening chronic condition that has put millions of Californians and Americans in an impossible situation of having to ration their care due to the high cost of insulin. We are thrilled to partner with California in the mission to lower the price of insulin and help people with diabetes live longer, healthier lives. At Civica, we are committed to making healthcare more affordable and accessible for all.
California is making a bold move with a $50 million dollar investment towards the development, manufacture and distribution of Civica’s low-cost insulins! This groundbreaking effort brings together nearly every corner of the diabetes ecosystem, including the diabetes community, philanthropists, hospital systems, payers, clinical trial experts, drug substance manufacturers, and leading pen and vial manufacturers. All partners are united in the mission to make low-cost insulins available to people living with diabetes.
California is leading the charge in providing accessible and affordable health care to all, and Governor Gavin Newsom is proud to announce the state’s partnership with Civica to bring true price competition to the insulin drug market.
This is a game changer in reducing the high cost of insulin and addressing health inequities across the state. By partnering with Civica, California is making sure that no one is left behind when it comes to obtaining the lifesaving medication they need.
Civica and CalRx have teamed up to provide access to affordable insulins with single, low transparent prices. Introducing three insulins – glargine, lispro, and aspart – available both in vials and prefilled pens under the CalRx label, these biologics are expected to be interchangeable with Lantus, Humalog, and Novolog respectively.
Excitingly, the manufacturer suggested retail price for each 10 mL vial will be no more than $30 and for a box of five 3 mL pre-filled pens, no more than $55 – a substantial discount compared to prices charged to uninsured individuals today. Insured Californians who currently pay cost sharing amounts for their insulin will benefit from these savings too.
The next step in our partnership is to explore the feasibility of establishing an insulin manufacturing facility in California. Through this collaboration, our aim is to revolutionize the insulin market and provide even more benefits to those relying on this vital medicine. Together, we can make a difference and bring much-needed relief to people in need.
Civica Inc. is a revolutionary nonprofit organization that is shaking up the healthcare industry. Established in 2018, Civica Rx and Civica are dedicated to increasing the reliability of the drug supply chain, while reducing drug shortages and associated high costs. This ambitious project is led by a brilliant team of healthcare and pharmaceutical industry experts, and is making a real difference in the lives of people across the United States.
Civica, the leading health system provider in the United States, has welcomed an impressive 55 health systems to its network, representing more than 1,550 hospitals and a staggering one-third of all hospital beds across the country! With this impressive collaboration, Civica is fast becoming the go-to provider for healthcare systems nationwide.
At Civica, our mission is to make quality generic medications accessible and affordable for all. We believe in putting the needs of patients first, and that’s why our number one policy is to always do what is in the best interests of those we serve. We strive to ensure that everyone has the medication they need to live healthier, happier lives.
Civica is making a major investment in the Petersburg, Virginia area with the construction of an essential medicines manufacturing facility that will revolutionize patient care. The facility, which is expected to begin test runs by late 2023, will produce sterile injectable medications for use in hospitals, emergency rooms, intensive-care units, surgeries, and other serious treatments. Among the products to be manufactured are insulin vials and prefilled pens, making them available for nationwide distribution.
California is leading the way in tackling drug affordability with the CalRx program. Announced in January 2019, Governor Newsom took decisive action to make drugs more affordable for Californians, signing the California Affordable Drug Manufacturing Act of 2020 (Pan, SB 852, Chapter 207, Statutes of 2020), into law.
Through CalRx, the State of California will be able to develop, produce, and distribute generic drugs at low cost, providing much needed relief to those struggling to pay for their medications.
The State is taking steps to reduce the burden of prescription drug costs, particularly when a generic or biosimilar medication is available yet the pharmaceutical market has failed to lower the price. Through targeted action, the State is committed to ensuring that consumers have access to cost-effective medications.
CalRx is taking a unique approach to procuring prescription drugs—seeking out deep, mutually beneficial partnerships with companies that share the State’s goals. These partnerships go beyond traditional procurement models, allowing for a more meaningful and beneficial experience for all involved.